Skip to main content
. Author manuscript; available in PMC: 2009 Feb 20.
Published in final edited form as: Vaccine. 2008 Jan 10;26(8):1098–1110. doi: 10.1016/j.vaccine.2007.12.024

Table 1.

Study design of DP6−001 clinical trial

DNA Prime Phase Protein Boost Phase
Group Plasmids (6) Dose Route Time (weeks) Proteins (5) Dose Route Time (weeks)
A
(n = 10)		 gp120 (A, B, Bal, C, E) + Gag (C) 1.2 mg ID 0, 4, 12 gp120 (A, B, Bal, C, E) 0.375 mg IM 20, 28
B
(n = 11)		 gp120 (A, B, Bal, C, E) + Gag (C) 1.2 mg IM 0, 4, 12 gp120 (A, B, Bal, C, E) 0.375 mg IM 20, 28
C
(n = 6)		 gp120 (A, B, Bal, C, E) + Gag (C) 7.2 mg IM 0, 4, 12 gp120 (A, B, Bal, C, E) 0.375 mg IM 20

HIV-1 viral strains (GeneBank accession number) used for DNA or protein vaccines

A: 92UG037.8 (U09127)

B: 92US715.6 (U08451)

Bal: Ba-L (M68893)

C: 96ZM651 (AF286224)

E: 93TH976.17 (U08458)